ClinicalTrials.gg
CompletedNCT00402324Updated Jun 3, 2009Results posted

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

A Phase 4 interventional study of olanzapine and placebo in Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-06-03.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Whether treatment with olanzapine in combination with mood stabilizer reduces symptoms of both mania and depression more than treatment with mood stabilizer alone, in patients with a mixed episode of bipolar I disorder.

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Mixed episode associated with Bipolar I
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with a mixed episode of bipolar I disorder.
  • Have had at least one previous manic or mixed episode associated with bipolar disorder
  • You must be between 18 and 60 years old.
  • You must be able to visit the doctor's office three times in the first week and then once every week for the next five weeks.
  • If you are a female, you must have a negative pregnancy test and be using an effective method of .

Exclusion criteria

Exclusion Criteria:

  • You have a diagnosis of schizophrenia, schizoaffective disorder or substance abuse or dependence.
  • You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood.
  • Have required a recent thyroid hormone supplement to treat hypothyroidism (must have been on a stable dose of the medication for at least 2 months prior to Visit 3).
  • You are allergic to any of the medications involved in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    1

    olanzapine and divalproex

    Drug: olanzapine · Drug: divalproex

  • Placebo comparator
    2

    placebo and divalproex

    Drug: placebo · Drug: divalproex

Interventions

  • 15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).

    Also known as: LY170053, Zyprexa

  • Drugplacebo

    placebo, capsules, by mouth every evening, daily, for 6 weeks.

  • dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).

06

What researchers measure

Primary outcomes

  1. Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint.

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline to endpoint (6 weeks)

  2. Mean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint.

    The 21-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60.

    Time frame: Baseline to endpoint (6 weeks)

Secondary outcomes

  1. Number of Participants Meeting the Criteria for Mixed Onset of Action

    The original outcome measure was Time to Mixed Onset of Action (at least a 25% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.

    Time frame: Baseline to endpoint (6 weeks)

  2. Number of Participants Meeting the Criteria for Mixed Response

    The original outcome measure was Time to Mixed Response(at least a 50% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.

    Time frame: baseline to endpoint (6 weeks)

  3. Mean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint

    CGI-BP Severity is used by the clinician to record the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline to endpoint (6 weeks)

  4. Number of Patients Hospitalized Due to Relapse of Mania or Depression.

    Number of participants hospitalized as a result of relapse of mania or depression.

    Time frame: Baseline to endpoint (6 weeks)

  5. Clinically Significant Laboratory Values - Fasting Cholesterol Change From Baseline

    Change from Baseline to endpoint in cholesterol: value of cholesterol measure at endpoint minus the value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  6. Clinically Significant Laboratory Values - Fasting Triglycerides Change From Baseline

    Change from baseline to endpoint in triglycerides: Value of triglyceride measure at endpoint minus value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  7. Clinically Significant Laboratory Values - Fasting Blood Glucose Change From Baseline

    Change from baseline to endpoint in fasting blood glucose: Value of fasting blood glucose measure at endpoint minus value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  8. Clinically Significant Laboratory Values - Bilirubin Total Change From Baseline

    Change from baseline to endpoint in bilirubin total: Value of bilirubin total measure at endpoint minus value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  9. Clinically Significant Vital Signs - Body Mass Index Change From Baseline

    Change from baseline to endpoint in body mass index (an estimate of body fat derived by dividing body weight by height squared): Value of body mass index measure at endpoint minus value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  10. Clinically Significant Vital Signs - Weight Change From Baseline

    Change from baseline to endpoint: Value of weight measure at endpoint minus value at baseline.

    Time frame: Baseline to endpoint (6 weeks)

  11. Clinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%)

    Percentages of participants in each group who experienced an increase in weight of at least 7% from baseline to endpoint.

    Time frame: Baseline to endpoint (6 weeks)

07

Results

Posted May 27, 2009

Participant flow

Participant flow — Overall Study
MilestoneOlanzapinePlacebo
Started101101
Completed5860
Not completed4341
Withdrew: Lost to follow-up1111
Withdrew: Protocol entry criteria not met54
Withdrew: Protocol violation87
Withdrew: Withdrawal by subject52
Withdrew: Physician decision24
Withdrew: Sponsor decision45
Withdrew: Lack of efficacy14
Withdrew: Adverse event64
Withdrew: Death10

Outcome measures

PrimaryMean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint.

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Least squares mean · units on a scale
Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint.
units on a scaleOlanzapinePlacebo
Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint.-10.15 ± 0.44-7.68 ± 0.44
Statistical analysis
  • Olanzapine vs Placebo · Mixed Models Analysis · p = <0.001 (All tests of treatment effects will be conducted at a two-sided alpha level of 0.05 unless otherwise stated.)Mixed Model Repeated Measures (MMRM) Change = Therapy PooledINV Visit Baseline Baseline\*Visit Therapy\*Visit. P-value from therapy term in model.
PrimaryMean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint.

The 21-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Least squares mean · units on a scale
Mean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint.
units on a scaleOlanzapinePlacebo
Mean Change in Hamilton Depression Rating Scale-21 (HAMD) Scores From Baseline to Endpoint.-9.37 ± 0.55-7.69 ± 0.54
Statistical analysis
  • Olanzapine vs Placebo · Mixed Models Analysis · p = 0.022 (All tests of treatment effects will be conducted at a two-sided alpha level of 0.05 unless otherwise stated.)Mixed Model Repeated Measures (MMRM) Change = Therapy PooledINV Visit Baseline Baseline\*Visit Therapy\*Visit. P-value from therapy term in model.
SecondaryNumber of Participants Meeting the Criteria for Mixed Onset of Action

The original outcome measure was Time to Mixed Onset of Action (at least a 25% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Number · participants
Number of Participants Meeting the Criteria for Mixed Onset of Action
participantsOlanzapinePlacebo
Number of Participants Meeting the Criteria for Mixed Onset of Action81 (3 to 15)71 (4 to 45)
Statistical analysis
  • Olanzapine vs Placebo · Fisher Exact · p = 0.100
SecondaryNumber of Participants Meeting the Criteria for Mixed Response

The original outcome measure was Time to Mixed Response(at least a 50% reduction on HAMD and YMRS total scores from baseline); however since upper limit of measure of dispersion could not be computed by observed data, which is not allowed on this system, number of patients with event are presented instead.

Time frame:
baseline to endpoint (6 weeks)
Reported as:
Number · participants
Number of Participants Meeting the Criteria for Mixed Response
participantsOlanzapinePlacebo
Number of Participants Meeting the Criteria for Mixed Response54 (9 to —)40 (13 to —)
Statistical analysis
  • Olanzapine vs Placebo · Fisher Exact · p = 0.048
SecondaryMean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint

CGI-BP Severity is used by the clinician to record the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Least squares mean · units on a scale
Mean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint
units on a scaleOlanzapinePlacebo
Mean Change in Clinical Global Impression for Bipolar Illness Severity (CGI-BP) From Baseline to Endpoint-1.34 ± 0.11-1.06 ± 0.11
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.056Type III sums of squares of ANCOVA model: Change= TRT + Pooled Investigator + Baseline.
SecondaryNumber of Patients Hospitalized Due to Relapse of Mania or Depression.

Number of participants hospitalized as a result of relapse of mania or depression.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Number · participants
Number of Patients Hospitalized Due to Relapse of Mania or Depression.
participantsOlanzapinePlacebo
Number of Patients Hospitalized Due to Relapse of Mania or Depression.10
SecondaryClinically Significant Laboratory Values - Fasting Cholesterol Change From Baseline

Change from Baseline to endpoint in cholesterol: value of cholesterol measure at endpoint minus the value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Mean · milligrams per deciliter
Clinically Significant Laboratory Values - Fasting Cholesterol Change From Baseline
milligrams per deciliterOlanzapinePlacebo
Total Cholesterol Baseline191.37 ± 41.23192.25 ± 44.45
Total Cholesterol Change from Baseline-7.80 ± 31.77-8.72 ± 28.80
Low Density Lipoprotein Baseline (N=62,N=64)115.32 ± 38.82111.01 ± 36.74
Low Density Lipoprotein Change (N=62,N=64)-9.22 ± 27.31-9.77 ± 28.05
High Density Lipoprotein Baseline53.76 ± 12.0351.48 ± 11.64
High Density Lipoprotein Change from Baseline-3.24 ± 10.02-1.22 ± 8.90
Statistical analysis
  • Olanzapine vs Placebo · ANOVA · p = 0.657 (P-value for Total Cholesterol Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
  • Olanzapine vs Placebo · ANOVA · p = 0.924 (P-value for Low Density Lipoprotein Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
  • Olanzapine vs Placebo · ANOVA · p = 0.122 (P-value for High Density Lipoprotein Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
SecondaryClinically Significant Laboratory Values - Fasting Triglycerides Change From Baseline

Change from baseline to endpoint in triglycerides: Value of triglyceride measure at endpoint minus value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Mean · milligrams per deciliter
Clinically Significant Laboratory Values - Fasting Triglycerides Change From Baseline
milligrams per deciliterOlanzapinePlacebo
Baseline111.46 ± 61.54139.75 ± 77.22
Change from Baseline22.91 ± 67.7016.80 ± 73.25
Statistical analysis
  • Olanzapine vs Placebo · ANOVA · p = 0.293 (P-value for Fasting Triglycerides Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
SecondaryClinically Significant Laboratory Values - Fasting Blood Glucose Change From Baseline

Change from baseline to endpoint in fasting blood glucose: Value of fasting blood glucose measure at endpoint minus value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Mean · milligrams per deciliter
Clinically Significant Laboratory Values - Fasting Blood Glucose Change From Baseline
milligrams per deciliterOlanzapinePlacebo
Baseline91.81 ± 11.9891.90 ± 10.13
Change from Baseline6.93 ± 23.72-0.55 ± 14.00
Statistical analysis
  • Olanzapine vs Placebo · ANOVA · p = 0.007 (P-value for Fasting Blood Glucose Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
SecondaryClinically Significant Laboratory Values - Bilirubin Total Change From Baseline

Change from baseline to endpoint in bilirubin total: Value of bilirubin total measure at endpoint minus value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Mean · micromoles per Liter
Clinically Significant Laboratory Values - Bilirubin Total Change From Baseline
micromoles per LiterOlanzapinePlacebo
Baseline6.50 ± 3.466.65 ± 3.43
Change from Baseline-1.56 ± 2.99-0.74 ± 3.03
Statistical analysis
  • Olanzapine vs Placebo · ANOVA · p = 0.046 (P-value for Bilirubin Total Change from Baseline)Type III sums of squares of ANOVA model: Ranked Change= Treatment + Pooled Investigator
SecondaryClinically Significant Vital Signs - Body Mass Index Change From Baseline

Change from baseline to endpoint in body mass index (an estimate of body fat derived by dividing body weight by height squared): Value of body mass index measure at endpoint minus value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Least squares mean · kilograms per square meters
Clinically Significant Vital Signs - Body Mass Index Change From Baseline
kilograms per square metersOlanzapinePlacebo
Clinically Significant Vital Signs - Body Mass Index Change From Baseline1.18 ± 0.120.26 ± 0.12
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = <0.001Type III sums of squares of ANCOVA model: Change= Treatment + Pooled Investigator + Baseline
SecondaryClinically Significant Vital Signs - Weight Change From Baseline

Change from baseline to endpoint: Value of weight measure at endpoint minus value at baseline.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Least squares mean · kilograms
Clinically Significant Vital Signs - Weight Change From Baseline
kilogramsOlanzapinePlacebo
Clinically Significant Vital Signs - Weight Change From Baseline3.34 ± 0.340.70 ± 0.34
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = <0.001Type III sums of squares of ANCOVA model: Change= Treatment + Pooled Investigator + Baseline
SecondaryClinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%)

Percentages of participants in each group who experienced an increase in weight of at least 7% from baseline to endpoint.

Time frame:
Baseline to endpoint (6 weeks)
Reported as:
Number · percentage of participants
Clinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%)
percentage of participantsOlanzapinePlacebo
Clinically Significant Vital Signs - Percentage of Participants With Baseline-to-Endpoint Weight Increase of at Least Seven Percent (7%)223
Statistical analysis
  • Olanzapine vs Placebo · Fisher Exact · p = <0.001

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine———
Placebo———
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventOlanzapinePlacebo
AstheniaGeneral disorders0/1011/101
Chest painGeneral disorders0/1011/101
DeathGeneral disorders1/1010/101
Acute hepatic failureHepatobiliary disorders1/1010/101
Head injuryInjury, poisoning and procedural complications1/1010/101
OverdoseInjury, poisoning and procedural complications0/1011/101
Road traffic accidentInjury, poisoning and procedural complications1/1010/101
Skin lacerationInjury, poisoning and procedural complications0/1011/101
HypoaesthesiaNervous system disorders0/1011/101
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1011/101
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOlanzapinePlacebo
SedationNervous system disorders24/1014/101
Weight increasedInvestigations21/1014/101
SomnolenceNervous system disorders21/1016/101
Dry mouthGastrointestinal disorders13/1013/101
Increased appetiteMetabolism and nutrition disorders13/1015/101
FatigueGeneral disorders10/1014/101
TremorNervous system disorders9/1010/101
NasopharyngitisInfections and infestations4/1017/101
HeadacheNervous system disorders5/1017/101
Oedema peripheralGeneral disorders6/1011/101

Baseline characteristics

Age Continuous
Age Continuous(years)OlanzapinePlaceboTotal
Mean38.61 ± 11.2038.52 ± 11.0738.56 ± 11.11
Sex: Female, Male
Sex: Female, Male(Participants)OlanzapinePlaceboTotal
Female6158119
Male404383
Region of Enrollment
Region of Enrollment(participants)OlanzapinePlaceboTotal
United States101101202
Race/Ethnicity
Race/Ethnicity(participants)OlanzapinePlaceboTotal
Caucasian4656102
African Descent382967
Hispanic151328
Native American123
East Asian112
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meters)OlanzapinePlaceboTotal
Mean30.73 ± 8.9931.72 ± 8.2931.23 ± 8.64
Body Weight
Body Weight(kilograms)OlanzapinePlaceboTotal
Mean87.33 ± 24.1790.75 ± 23.7089.04 ± 23.94
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hialeah, Florida 33016, United States
09

References and documents

Publications

  • Houston JP, Gatz JL, Degenhardt EK, Jamal HH. Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study. BMC Res Notes. 2010 Nov 2;3:276. doi: 10.1186/1756-0500-3-276. PubMed 21044339 ↗
  • Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009 Nov;70(11):1540-7. doi: 10.4088/JCP.08m04895yel. Epub 2009 Sep 22. Erratum In: J Clin Psychiatry. 2010 Jan;71(1):93. J Clin Psychiatry. 2011 Aug;72(8):1157. PubMed 19778495 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2006
First posted
Nov 22, 2006
Start
Dec 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
May 27, 2009
Last update
Jun 3, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402324
First posted
Nov 22, 2006
Start date
Dec 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
May 27, 2009
Last update
Jun 3, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion